RATIONALE: Simvastatin inhibits inflammatory responses in vitro and in murine models of lung inflammation in vivo. As simvastatin modulates a number of the underlying processes described in acute lung injury (ALI), it may be a potential therapeutic option. OBJECTIVES: To investigate in vivo if simvastatin modulates mechanisms important in the development of ALI in a model of acute lung inflammation induced by inhalation of lipopolysaccharide (LPS) in healthy human volunteers. METHODS:Thirty healthy subjects were enrolled in a double-blind, placebo-controlled study. Subjects were randomized to receive 40 mg or 80 mg of simvastatin or placebo (n = 10/group) for 4 days before inhalation of 50 microg LPS. Measurements were performed in bronchoalveolar lavage fluid (BALF) obtained at 6 hours and plasma obtained at 24 hours after LPS challenge. Nuclear translocation of nuclear factor-kappaB (NF-kappaB) was measured in monocyte-derived macrophages. MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). There was no significant difference between simvastatin 40 mg and 80 mg. BALF from subjects post-LPS inhalation induced a threefold up-regulation in nuclear NF-kappaB in monocyte-derived macrophages (P < 0.001); pretreatment with simvastatin reduced this by 35% (P < 0.001). CONCLUSIONS:Simvastatin has antiinflammatory effects in the pulmonary and systemic compartment in humans exposed to inhaled LPS.
RCT Entities:
RATIONALE: Simvastatin inhibits inflammatory responses in vitro and in murine models of lung inflammation in vivo. As simvastatin modulates a number of the underlying processes described in acute lung injury (ALI), it may be a potential therapeutic option. OBJECTIVES: To investigate in vivo if simvastatin modulates mechanisms important in the development of ALI in a model of acute lung inflammation induced by inhalation of lipopolysaccharide (LPS) in healthy human volunteers. METHODS: Thirty healthy subjects were enrolled in a double-blind, placebo-controlled study. Subjects were randomized to receive 40 mg or 80 mg of simvastatin or placebo (n = 10/group) for 4 days before inhalation of 50 microg LPS. Measurements were performed in bronchoalveolar lavage fluid (BALF) obtained at 6 hours and plasma obtained at 24 hours after LPS challenge. Nuclear translocation of nuclear factor-kappaB (NF-kappaB) was measured in monocyte-derived macrophages. MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). There was no significant difference between simvastatin 40 mg and 80 mg. BALF from subjects post-LPS inhalation induced a threefold up-regulation in nuclear NF-kappaB in monocyte-derived macrophages (P < 0.001); pretreatment with simvastatin reduced this by 35% (P < 0.001). CONCLUSIONS:Simvastatin has antiinflammatory effects in the pulmonary and systemic compartment in humans exposed to inhaled LPS.
Authors: Reimar W Thomsen; Anders Riis; Jette B Kornum; Steffen Christensen; Søren P Johnsen; Henrik T Sørensen Journal: Arch Intern Med Date: 2008-10-27
Authors: Conor J McCann; Ben M Glover; Ian B A Menown; Michael J Moore; Jane McEneny; Colum G Owens; Bernie Smith; Peter C Sharpe; Ian S Young; Jennifer A Adgey Journal: Eur Heart J Date: 2008-08-05 Impact factor: 29.983
Authors: Cecilia M O'Kane; Joseph J Boyle; Donna E Horncastle; Paul T Elkington; Jon S Friedland Journal: J Immunol Date: 2007-03-15 Impact factor: 5.422
Authors: U Hamid; A Krasnodembskaya; M Fitzgerald; M Shyamsundar; A Kissenpfennig; C Scott; E Lefrancais; M R Looney; R Verghis; J Scott; A J Simpson; J McNamee; D F McAuley; C M O'Kane Journal: Thorax Date: 2017-01-12 Impact factor: 9.139
Authors: Carolyn S Calfee; Kevin L Delucchi; Pratik Sinha; Michael A Matthay; Jonathan Hackett; Manu Shankar-Hari; Cliona McDowell; John G Laffey; Cecilia M O'Kane; Daniel F McAuley Journal: Lancet Respir Med Date: 2018-08-02 Impact factor: 30.700
Authors: Alessandro Morandi; Christopher G Hughes; Jennifer L Thompson; Pratik P Pandharipande; Ayumi K Shintani; Eduard E Vasilevskis; Jin H Han; James C Jackson; Daniel T Laskowitz; Gordon R Bernard; E Wesley Ely; Timothy D Girard Journal: Crit Care Med Date: 2014-08 Impact factor: 7.598
Authors: Gavin D Perkins; Nazim Nathani; Alex G Richter; Daniel Park; Murali Shyamsundar; Ritva Heljasvaara; Taina Pihlajaniemi; Mav Manji; W Tunnicliffe; Danny McAuley; Fang Gao; David R Thickett Journal: Crit Care Date: 2009-04-09 Impact factor: 9.097